Most importantly, he found differential expression changes that always led to prosurvival adaptation of senescent cells ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 8.97%, which has investors questioning if this is right time to buy.

Ascentage Pharma Group International’s AAPG share price has dipped by 6.94%, which has investors questioning if this is right ...

John Seymour, MBBS, FRACP, PhD, explains why BCL-2 was considered an undruggable target for so long and what led to the development of effective BCL-2 inhibitors.

Chardan lowered the firm’s price target on Unity Biotechnology (UBX) to $4 from $6 and keeps a Buy rating on the shares after the company ...

The topline results come from the California company’s phase 2b study, dubbed Aspire, which is evaluating intravitreal UBX1325, a small molecule designed to inhibit BCL-xL. The double-masked ...

UBX1325 is UNITY Biotechnology’s novel BCL-xL inhibitor with a unique mechanism of action. The data readout from the mid-stage DME study demonstrated that treatment with the candidate resulted ...